✦ LIBER ✦

First-in-human phase I clinical trial of a recombinant vesicular stomatitis virus (rVSV)-based preventive HIV-1 vaccine

✍ Scribed by JD Fuchs, I Frank, N Kochar, M Elizaga, M Allen, D Carter, N Frahm…

Book ID: 120691189
Publisher: BioMed Central
Year: 2012
Tongue: English
Weight: 64 KB
Volume: 9
Category: Article
ISSN: 1742-4690
DOI: 10.1186/1742-4690-9-S2-P134

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

First-in-human phase 1 trial of the safe

First-in-human phase 1 trial of the safety and immunogenicity of a recombinant adenovirus serotype 5 HVR48 (rAd5HVR48) HIV-1 vaccine

✍ SR Walsh, MS Seaman, JA Johnson, RP Tucker, KH Krause, M Weijtens, MG Pau… 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 65 KB

Phase I clinical trial safety of DNA- an

Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers

✍ Inese Cebere; Lucy Dorrell; Helen McShane; Alison Simmons; Sheena McCormack; Cla 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 289 KB

Attenuation of Recombinant Vesicular Sto

Attenuation of Recombinant Vesicular Stomatitis Virus-Human Immunodeficiency Virus Type 1 Vaccine Vectors by Gene Translocations and G Gene Truncation Reduces Neurovirulence and Enhances Immunogenicity in Mice

✍ Cooper, D.; Wright, K. J.; Calderon, P. C.; Guo, M.; Nasar, F.; Johnson, J. E.; 📂 Article 📅 2007 🏛 American Society for Microbiology 🌐 English ⚖ 711 KB

Safety and immunogenicity of a modified

Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)

✍ Felipe García; Juan Carlos López Bernaldo de Quirós; Carmen E. Gómez; Beatriz Pe 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 533 KB